Stock Chart

GYRE

$7.25 +3.57%
Score: 47.3 HOLD
Pro
Screener
Vol: 0.47x (vs SPY: 0.7x | vs QQQ: 0.7x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Rising Channel weak / forming — below our quality gate quality 44/100
A Rising Channel is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Lower rail breaks first 80% of the time (n=1,744) — a trend-exit tell, not a crash call
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About GYRE - Gyre Therapeutics, Inc. Common Stock

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable …

Key Statistics

Market Cap $777M

This GYRE stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track GYRE's price movements with trendlines, gamma walls, and key support/resistance levels.